India’s “silent epidemic”: 2 diagnostic stocks to watch as lifestyle diseases surge
India’s ₹26B diagnostic boom is reshaping healthcare. Discover how Dr Lal PathLabs and Thyrocare Technologies are revolutionising India’s medical future.

What's Your Reaction?











